Loading [MathJax]/jax/output/SVG/jax.js
Review

Exploring the multi-drug resistance (MDR) inhibition property of Sildenafil: phosphodiesterase 5 as a therapeutic target and a potential player in reversing MDR for a successful breast cancer treatment

  • Received: 23 September 2024 Revised: 15 February 2025 Accepted: 05 March 2025 Published: 22 April 2025
  • In recent years, there has been an increase in both the incidence and mortality of breast cancer. Globally, breast cancer is ranked as the main root of cancer-related death in women. Multidrug resistance (MDR) is identified as a primary cause of treatment failure in anticancer chemotherapy. This makes multidrug resistance an interesting therapeutic target in breast cancer. Therefore, elucidation of the molecular mechanisms involved in chemoresistance is essential. Phosphodiesterase 5 (PDE5) cross-talks with nitric oxide/cyclic guanosine monophosphate (NO/cGMP), Wnt/β-catenin, and PI3K/Akt signaling pathways to upregulate the expression of ABC transporters and increase cGMP efflux. This enhances multidrug resistance and impacts cellular processes such as proliferation, apoptosis, and angiogenesis. Thus, further research on the identification of possible factors in the reversal of MDR in breast cancer is necessary. Sildenafil is a selective phosphodiesterase type 5 inhibitor that is commonly utilized as first-line therapy in treating erectile dysfunction. Its safety profile and tolerability have encouraged researchers to develop an interest in further investigations into its beneficial uses, especially its chemo-preventive activity in managing breast cancer. In this review, we critically examined the central role played by PDE5 in activating several pathways involved in MDR in breast cancer. Given that sildenafil is a selective PDE5 inhibitor, we provide insight into its modulatory effects and interactions with signaling pathways targeted by PDE5 to overcome MDR in breast cancer.

    Citation: Anne A. Adeyanju, Wonderful B. Adebagbo, Olorunfemi R. Molehin, Omolola R. Oyenihi. Exploring the multi-drug resistance (MDR) inhibition property of Sildenafil: phosphodiesterase 5 as a therapeutic target and a potential player in reversing MDR for a successful breast cancer treatment[J]. AIMS Medical Science, 2025, 12(2): 145-170. doi: 10.3934/medsci.2025010

    Related Papers:

    [1] Gilberto González-Parra, Cristina-Luisovna Pérez, Marcos Llamazares, Rafael-J. Villanueva, Jesus Villegas-Villanueva . Challenges in the mathematical modeling of the spatial diffusion of SARS-CoV-2 in Chile. Mathematical Biosciences and Engineering, 2025, 22(7): 1680-1721. doi: 10.3934/mbe.2025062
    [2] Fang Wang, Lianying Cao, Xiaoji Song . Mathematical modeling of mutated COVID-19 transmission with quarantine, isolation and vaccination. Mathematical Biosciences and Engineering, 2022, 19(8): 8035-8056. doi: 10.3934/mbe.2022376
    [3] Yangyang Yu, Yuan Liu, Shi Zhao, Daihai He . A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. Mathematical Biosciences and Engineering, 2022, 19(10): 10361-10373. doi: 10.3934/mbe.2022485
    [4] Sarafa A. Iyaniwura, Rabiu Musa, Jude D. Kong . A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Mathematical Biosciences and Engineering, 2023, 20(3): 5379-5412. doi: 10.3934/mbe.2023249
    [5] Anichur Rahman, Muaz Rahman, Dipanjali Kundu, Md Razaul Karim, Shahab S. Band, Mehdi Sookhak . Study on IoT for SARS-CoV-2 with healthcare: present and future perspective. Mathematical Biosciences and Engineering, 2021, 18(6): 9697-9726. doi: 10.3934/mbe.2021475
    [6] Matthew Hayden, Bryce Morrow, Wesley Yang, Jin Wang . Quantifying the role of airborne transmission in the spread of COVID-19. Mathematical Biosciences and Engineering, 2023, 20(1): 587-612. doi: 10.3934/mbe.2023027
    [7] A. M. Elaiw, Raghad S. Alsulami, A. D. Hobiny . Global dynamics of IAV/SARS-CoV-2 coinfection model with eclipse phase and antibody immunity. Mathematical Biosciences and Engineering, 2023, 20(2): 3873-3917. doi: 10.3934/mbe.2023182
    [8] Rahat Zarin, Usa Wannasingha Humphries, Amir Khan, Aeshah A. Raezah . Computational modeling of fractional COVID-19 model by Haar wavelet collocation Methods with real data. Mathematical Biosciences and Engineering, 2023, 20(6): 11281-11312. doi: 10.3934/mbe.2023500
    [9] Salman Safdar, Calistus N. Ngonghala, Abba B. Gumel . Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States. Mathematical Biosciences and Engineering, 2023, 20(1): 179-212. doi: 10.3934/mbe.2023009
    [10] Hiroshi Nishiura, Seiko Fujiwara, Akifumi Imamura, Takuma Shirasaka . HIV incidence before and during the COVID-19 pandemic in Japan. Mathematical Biosciences and Engineering, 2024, 21(4): 4874-4885. doi: 10.3934/mbe.2024215
  • In recent years, there has been an increase in both the incidence and mortality of breast cancer. Globally, breast cancer is ranked as the main root of cancer-related death in women. Multidrug resistance (MDR) is identified as a primary cause of treatment failure in anticancer chemotherapy. This makes multidrug resistance an interesting therapeutic target in breast cancer. Therefore, elucidation of the molecular mechanisms involved in chemoresistance is essential. Phosphodiesterase 5 (PDE5) cross-talks with nitric oxide/cyclic guanosine monophosphate (NO/cGMP), Wnt/β-catenin, and PI3K/Akt signaling pathways to upregulate the expression of ABC transporters and increase cGMP efflux. This enhances multidrug resistance and impacts cellular processes such as proliferation, apoptosis, and angiogenesis. Thus, further research on the identification of possible factors in the reversal of MDR in breast cancer is necessary. Sildenafil is a selective phosphodiesterase type 5 inhibitor that is commonly utilized as first-line therapy in treating erectile dysfunction. Its safety profile and tolerability have encouraged researchers to develop an interest in further investigations into its beneficial uses, especially its chemo-preventive activity in managing breast cancer. In this review, we critically examined the central role played by PDE5 in activating several pathways involved in MDR in breast cancer. Given that sildenafil is a selective PDE5 inhibitor, we provide insight into its modulatory effects and interactions with signaling pathways targeted by PDE5 to overcome MDR in breast cancer.



    In this paper, we are concerned with the existence and multiplicity of weak solutions for the damped-like fractional differential system

    {ddt(p(t)(12 0Dξt(u(t))+12 tDξT(u(t))))+r(t)(12 0Dξt(u(t))+12 tDξT(u(t)))+q(t)u(t)=λF(t,u(t)),  a.e. t[0,T],u(0)=u(T)=0, (1.1)

    where 0Dξt and tDξT are the left and right Riemann-Liouville fractional integrals of order 0ξ<1, respectively, p,r,qC([0,T],R), L(t):=t0(r(s)/p(s))ds, 0<meL(t)p(t)M and q(t)p(t)0 for a.e. t[0,T], u(t)=(u1(t),u2(t),un(t))T, ()T denotes the transpose of a vector, n1 is a given positive integer, λ>0 is a parameter, F(t,x) is the gradient of F with respect to x=(x1,,xn)Rn, that is, F(t,x)=(Fx1,,Fxn)T, and there exists a constant δ(0,1) such that F:[0,T]ׯBδ0R (where ¯Bδ0 is a closed ball in RN with center at 0 and radius δ) satisfies the following condition

    (F0) F(t,x) is continuously differentiable in ¯Bδ0 for a.e. t[0,T], measurable in t for every x¯Bδ0, and there are aC(¯Bδ0,R+) and bL1([0,T];R+) such that

    |F(t,x)|a(|x|)b(t)

    and

    |F(t,x)|a(|x|)b(t)

    for all x¯Bδ0 and a.e. t[0,T].

    In recent years, critical point theory has been extensively applied to investigate the existence and multiplicity of fractional differential equations. An successful application to ordinary fractional differential equations with Riemann-Liouville fractional integrals was first given by [1], in which they considered the system

    {ddt((12 0Dξt(u(t))+12 tDξT(u(t))))=F(t,u(t)),  a.e. t[0,T],u(0)=u(T)=0. (1.2)

    They established the variational structure and then obtained some existence results for system (1.2). Subsequently, this topic attracted lots of attention and a series of existence and multiplicity results are established (for example, see [2,3,4,5,6,7,8,9,10,11,12] and reference therein). It is obvious that system (1.1) is more complicated than system (1.2) because of the appearance of damped-like term

    r(t)(12 0Dξt(u(t))+12 tDξT(u(t))).

    In [13], the variational functional for system (1.1) with λ=1 and N=1 has been established, and in [14], they investigated system (1.1) with λ=1, N=1 and an additional perturbation term. By mountain pass theorem and symmetric mountain pass theorem in [15] and a local minimum theorem in [16], they obtained some existence and multiplicity results when F satisfies superquadratic growth at infinity and some other reasonable conditions at origin.

    In this paper, motivated by the idea in [17,18], being different from those in [13,14], we consider the case that F has subquadratic growth only near the origin and no any growth condition at infinity. Our main tools are Ekeland's variational principle in [19], a variant of Clark's theorem in [17] and a cut-off technique in [18]. We obtain that system (1.1) has a ground state weak solution uλ if λ is in some given interval and then some estimates of uλ are given, and when F(t,x) is also even about x near the origin for a.e. t[0,T], for each given λ>0, system (1.1) has infinitely many weak solutions {uλn} with uλn0 as n. Next, we make some assumptions and state our main results.

    (f0) There exist constants M1>0 and 0<p1<2 such that

    F(t,x)M1|x|p1 (1.3)

    for all x¯Bδ0 and a.e. t[0,T].

    (f1) There exist constants M2>0 and 0<p2<p1<2 such that

    F(t,x)M2|x|p2 (1.4)

    for all x¯Bδ0 and a.e. t[0,T].

    (f0) There exist constants M1>0 and 0<p1<1 such that (1.3) holds.

    (f1) There exist constants M2>0 and 0<p2<p1<1 such that (1.4) holds.

    (f2) There exists a constant η(0,2) such that

    (F(t,x),x)ηF(t,x)

    for all x¯Bδ0 and a.e. t[0,T].

    (f3) F(t,x)=F(t,x) for all x¯Bδ0 and a.e. t[0,T].

    Theorem 1.1. Suppose that (F0), (f0), (f1) and (f2) hold. If

    0<λmin{|cos(πα)|2C,(1B)2p2(δ2)2p2|cos(πα)|2C},

    then system (1.1) has a ground state weak solution uλ satisfying

    uλ2p2min{1,(1B)2p2(δ2)2p2},uλ2p2{B2p2,(δ2)2p2}.

    where

    B=T2α12mΓ(α)(2α1)12,C=max{p,η}max{M1,M2}Tmaxt[0,T]eL(t)max{Bp1,Bp2}.

    If (f0) and (f1) are replaced by the stronger conditions (f0) and (f1), then (f2) is not necessary in Theorem 1.1. So we have the following result.

    Theorem 1.2. Suppose that (F0), (f0) and (f1) hold. If

    0<λmin{|cos(πα)|3C,(1B)2p1(δ2)2p1|cos(πα)|3C},

    then system (1.1) has a ground state weak solution uλ satisfying

    uλ2p1min{1,(1B)2p1(δ2)2p1},uλ2p1{B2p1,(δ2)2p1},

    where C=maxt[0,T]eL(t)max{(1+ρ0)a0BT0b(t)dt,M1p1TBp1,ρ0M1TBp1+1}, a0=maxs[0,δ]a(s) and ρ0=maxs[δ2,δ]|ρ(s)| and ρ(s)C1(R,[0,1]) is any given even cut-off function satisfying

    ρ(s)={1,if |s|δ/2,0,if |s|>δ. (1.5)

    Theorem 1.3. Suppose that (F0), (f0), (f1) and (f3) hold. Then for each λ>0, system (1.1) has a sequence of weak solutions {uλn} satisfying {uλn}0, as n.

    Remark 1.1. Theorem 1.1-Theorem 1.3 still hold even if r(t)0 for all t[0,T], that is, the damped-like term disappears, which are different from those in [2,3,4,5,6,7,8,9,10,11,12] because all those assumptions with respect to x in our theorems are made only near origin without any assumption near infinity.

    The paper is organized as follows. In section 2, we give some preliminary facts. In section 3, we prove Theorem 1.1–Theorem 1.3.

    In this section, we introduce some definitions and lemmas in fractional calculus theory. We refer the readers to [1,9,20,21,22]. We also recall Ekeland's variational principle in [19] and the variant of Clark's theorem in [17].

    Definition 2.1. (Left and Right Riemann-Liouville Fractional Integrals [22]) Let f be a function defined on [a,b]. The left and right Riemann-Liouville fractional integrals of order γ for function f denoted by aDγtf(t) and tDγbf(t), respectively, are defined by

    aDγtf(t)=1Γ(γ)ta(ts)γ1f(s)ds,t[a,b],γ>0,tDγbf(t)=1Γ(γ)bt(st)γ1f(s)ds,t[a,b],γ>0.

    provided the right-hand sides are pointwise defined on [a,b], where Γ>0 is the Gamma function.

    Definition 2.2. ([22]) For nN, if γ=n, Definition 2.1 coincides with nth integrals of the form

    aDntf(t)=1(n1)!ta(ts)n1f(s)ds,t[a,b],nN,tDnbf(t)=1(n1)!bt(ts)n1f(s)ds,t[a,b],nN.

    Definition 2.3. (Left and Right Riemann-Liouville Fractional Derivatives [22]) Let f be a function defined on [a,b]. The left and right Riemann-Liouville fractional derivatives of order γ for function f denoted by aDγtf(t) and tDγbf(t), respectively, are defined by

    aDγtf(t)=dndtnaDγntf(t)=1Γ(nγ)dndtn(ta(ts)nγ1f(s)ds),tDγbf(t)=(1)ndndtntDγnbf(t)=(1)nΓ(nγ)dndtn(bt(st)nγ1f(s)ds).

    where t[a,b],n1γ<n and nN. In particular, if 0γ<1, then

    aDγtf(t)=ddtaDγ1tf(t)=1Γ(1γ)ddt(ta(ts)γf(s)ds),t[a,b],tDγbf(t)=ddttDγ1bf(t)=1Γ(1γ)ddt(bt(st)γf(s)ds),t[a,b].

    Remark 2.1. ([9,13]) The left and right Caputo fractional derivatives are defined by the above-mentioned Riemann-Liuville fractional derivative. In particular, they are defined for function belonging to the space of absolutely continuous functions, which we denote by AC([a,b],RN). ACk([a,b],RN)(k=0,1,...) are the space of the function f such that fCk([a,b],RN). In particular, AC([a,b],RN)=AC1([a,b],RN).

    Definition 2.4. (Left and Right Caputo Fractional Derivatives [22]) Let γ0 and nN.

    (ⅰ) If γ(n1,n) and fACn([a,b],RN), then the left and right Caputo fractional derivatives of order γ for function f denoted by caDγtf(t) and ctDγbf(t), respectively, exist almost everywhere on [a,b]. caDγtf(t) and ctDγbf(t) are represented by

    caDγtf(t)=aDγntfn(t)=1Γ(nγ)(ta(ts)nγ1f(n)(s)ds),ctDγbf(t)=(1)n tDγnbfn(t)=(1)nΓ(nγ)(bt(st)nγ1f(n)(s)ds),

    respectively, where t[a,b]. In particular, if 0<γ<1, then

    caDγtf(t)=aDγ1tf(t)=1Γ(1γ)(ta(ts)γf(s)ds),t[a,b],ctDγbf(t)=tDγ1bf(t)=1Γ(1γ)(bt(st)γf(s)ds),t[a,b].

    (ⅱ) If γ=n1 and fACn([a,b],RN), then caDγtf(t) and ctDγbf(t) are represented by

    caDn1tf(t)=f(n1)(t),t[a,b],ctDn1bf(t)=(1)n1f(n1)(t),t[a,b].

    In particular, caD0tf(t)= ctD0bf(t)=f(t), t[a,b].

    Lemma 2.1. ([22]) The left and right Riemann-Liouville fractional integral operators have the property of a semigroup, i.e.

    aDγ1t(aDγ2tf(t))=aDγ1γ2tf(t),tDγ1b(tDγ2bf(t))=tDγ1γ2bf(t),γ1,γ2>0,

    in any point t[a,b] for continuous function f and for almost every point in [a,b] if the function fL1([a,b],RN).

    For 1r<, define

    uLr=(T0|u(t)|rdt)1r (2.1)

    and

    u=maxt[0,T]|u(t)|. (2.2)

    Definition 2.5. ([1]) Let 0<α1 and 1<p<. The fractional derivative space Eα,p0 is defined by closure of C0([0,T],RN) with respect to the norm

    uα,p=(T0|u(t)|pdt+T0|c0Dαtu(t)|pdt)1p. (2.3)

    Remark 2.2. ([9]) Eα,p0 is the space of functions uLp([0,T],RN) having an α-order Caputo fractional derivative c0Dαtu(t)Lp([0,T],RN) and u(0)=u(T)=0.

    Lemma 2.2. ([1]) Let 0<α1 and 1<p<. Eα,p0 is a reflexive and separable Banach space.

    Lemma 2.3. ([1]) Assume that 1<p< and α>1p. Then Eα,p0 compactly embedding in C([0,T],RN).

    Lemma 2.4. ([1]) Let 0<α1 and 1<p<. For all uEα,p0, we have

    uLpTαΓ(α+1)c0DαtuLp. (2.4)

    Moreover, if α>1p and 1p+1q=1, then

    uTα1pΓ(α)((α1)q+1)1qc0DαtuLp. (2.5)

    Definition 2.6. ([13]) Assume that X is a Banach space. An operator A:XX is of type (S)+ if, for any sequence {un} in X, unu and lim supn+A(un),unu0 imply unu.

    Let φ:XR. A sequence {un}X is called (PS) sequence if the sequence {un} satisfies

    φ(un) is bounded, φ(un)0.

    Furthermore, if every (PS) sequence {un} has a convergent subsequence in X, then one call that φ satisfies (PS) condition.

    Lemma 2.5. ([19]) Assume that X is a Banach space and φ:XR is Gˆateaux differentiable, lower semi-continuous and bounded from below. Then there exists a sequence {xn} such that

    φ(xn)infXφ,φ(xn)0.

    Lemma 2.6. ([17]) Let X be a Banach space, φC1(X,R). Assume φ satisfies the (PS) condition, is even and bounded below, and φ(0)=0. If for any kN, there exist a k-dimensional subspace Xk of X and ρk>0 such that supXkSpkφ<0, where Sρ={uX|u=ρ}, then at least one of the following conclusions holds.

    (ⅰ) There exist a sequence of critical points {uk} satisfying φ(uk)<0 for all k and uk0 as k.

    (ⅱ) There exists a constant r>0 such that for any 0<a<r there exists a critical point u such that u=a and φ(u)=0.

    Remark 2.3. ([17]) Lemma 2.6 implies that there exist a sequence of critical points uk0 such that φ(uk)0, φ(uk)0 and uk0 as k.

    Now, we establish the variational functional defined on the space Eα,20 with 12<α1. We follow the same argument as in [13] where the one-dimensional case N=1 and λ=1 for system (1.1) was investigated. For reader's convenience, we also present the details here. Note that L(t):=t0(r(s)/p(s))ds,0<meL(t)p(t)M and q(t)p(t)0 for a.e. t[0,T]. Then system (1.1) is equivalent to the system

    {ddt(eL(t)p(t)(12 0Dξt(u(t))+12 tDξT(u(t))))+eL(t)q(t)u(t)=λeL(t)F(t,u),  a.e. t[0,T],u(0)=u(T)=0. (2.6)

    By Lemma 2.1, for every uAC([0,T],RN), it is easy to see that system (2.6) is equivalent to the system

    {ddt[eL(t)p(t)(12 0Dξ2t(0Dξ2tu(t))+12 tDξ2T(tDξ2Tu(t)))]+eL(t)q(t)u(t)=λeL(t)F(t,u),  a.e. t[0,T],u(0)=u(T)=0, (2.7)

    where ξ[0,1).

    By Definition 2.4, we obtain that uAC([0,T],RN) is a solution of problem (2.7) if and only if u is a solution of the following system

    {ddt(eL(t)p(t)(12 0Dα1t(c0Dαtu(t))12 tDα1T(ctDαTu(t))))+eL(t)q(t)u(t)=λeL(t)F(t,u),u(0)=u(T)=0, (2.8)

    for a.e. t[0,T], where α=1ξ2(12,1]. Hence, the solutions of system (2.8) correspond to the solutions of system (1.1) if uAC([0,T],RN).

    In this paper, we investigate system (2.8) in the Hilbert space Eα,20 with the corresponding norm

    u=(T0eL(t)p(t)(|c0Dαtu(t)|2+|u(t)|2)dt)12.

    It is easy to see that u is equivalent to uα,2 and

    mT0|c0Dαtu(t)|2dtT0eL(t)p(t)|c0Dαtu(t)|2dtMT0|c0Dαtu(t)|2dt.

    So

    uL2TαmΓ(α+1)(T0eL(t)p(t)|c0Dαtu(t)|2dt)12,

    and

    uBu, (2.9)

    where

    B=T2α12mΓ(α)(2α1)12>0.

    (see [13]).

    Lemma 2.7. ([13]) If 12<α1, then for every uEα,20, we have

    |cos(πα)|u2T0eL(t)p(t)(c0Dαtu(t),ctDαTu(t))dt+T0eL(t)p(t)|u(t)|2dtmax{Mm|cos(πα)|,1}u2. (2.10)

    We follow the idea in [17] and [18]. We first modify and extend F to an appropriate ˜F defined by

    ˜F(t,x)=ρ(|x|)F(t,x)+(1ρ(|x|))M1|x|p1,  for all xRN,

    where ρ is defined by (1.5).

    Lemma 3.1. Let (F0), (f0), (f1) (or (f0), (f1)), (f2) and (f3) be satisfied. Then

    (˜F0) ˜F(t,x) is continuously differentiable in xRN for a.e. t[0,T], measurable in t for every xRN, and there exists bL1([0,T];R+) such that

    |˜F(t,x)|a0b(t)+M1|x|p1,|˜F(t,x)|(1+ρ0)a0b(t)+M1p1|x|p11+ρ0M1|x|p1

    for all xRN and a.e. t[0,T];

    (˜f0) ˜F(t,x)M1|x|p1 for all xRN and a.e. t[0,T];

    (˜f1) ˜F(t,x)max{M1,M2}(|x|p1+|x|p2) for all xRN and a.e. t[0,T];

    (˜f2) (˜F(t,x),x)θ˜F(t,x) for all xRN and a.e. t[0,T], where θ=max{p1,η};

    (˜f3) ˜F(t,x)=˜F(t,x) for all xRN and a.e. t[0,T].

    Proof. We only prove (˜f0), (˜f1) and (˜f2). (˜F0) can be proved by a similar argument by (F0). By the definition of ˜F(t,x), (f0) and (f1) (or (f0) and (f1)), we have

    M1|x|p1˜F(t,x)=F(t,x)M2|x|p2, if |x|δ/2,
    ˜F(t,x)=M1|x|p1, if |x|>δ,
    ˜F(t,x)F(t,x)+M1|x|p1M1|x|p1+M2|x|p2, if δ/2<|x|δ

    and

    ˜F(t,x)ρ(|x|)M1|x|p1+(1ρ(|x|))M1|x|p1=M1|x|p1, if δ/2<|x|δ.

    Hence, (˜f1) holds. Note that

    θ˜F(t,x)(˜F(t,x),x)=ρ(|x|)(θF(t,x)(F(t,x),x))+(θp1)(1ρ(|x|))M1|x|p1|x|ρ(|x|)(F(t,x)M1|x|p1).

    It is obvious that the conclusion holds for 0|x|δ/2 and |x|>δ. If δ/2<|x|δ, by using θp1, (f2), (˜f1) and the fact sρ(s)0 for all sR, we can get the conclusion (˜f2). Finally, since ρ(|x|) is even for all xRN, by (f3) and the definition of ˜F(t,x), it is easy to get (˜f3).

    Remark 3.1. From the proof of Lemma 3.1, it is easy to see that (F0), (f0) (or (f0)) and (f1) (or (f1)) independently imply (˜F0), (˜f0) and (˜f1), respectively.

    Consider the modified system

    {ddt(eL(t)p(t)(12 0Dα1t(c0Dαtu(t))12 tDα1T(ctDαTu(t))))+eL(t)q(t)u(t)=λeL(t)˜F(t,u),u(0)=u(T)=0, (3.1)

    for a.e. t[0,T], where α=1ξ2(12,1].

    If the equality

    T0eL(t)[12p(t)((c0Dαtu(t),ctDαTv(t))+(ctDαTu(t),c0Dαtv(t)))+p(t)(u(t),v(t))+(q(t)p(t))(u(t),v(t))λ(˜F(t,u(t)),v(t))]dt=0

    holds for every vEα,20, then we call uEα,20 is a weak solution of system (3.1).

    Define the functional ˜J:Eα,20R by

    ˜J(u)=T0eL(t)[12p(t)((c0Dαtu(t),ctDαTu(t))+|u(t)|2)+12(q(t)p(t))|u(t)|2λ˜F(t,u(t))]dt, for all uEα,20.

    Then (˜F0) and Theorem 6.1 in [9] imply that ˜JC1(Eα,20,R), and for every u,vEα,20, we have

    ˜J(u),v=T0eL(t)[12p(t)((c0Dαtu(t),ctDαTv(t))+(ctDαTu(t),c0Dαtv(t)))+p(t)(u(t),v(t))+(q(t)p(t))(u(t),v(t))λ(˜F(t,u(t)),v(t))]dt.

    Hence, a critical point of ˜J(u) corresponds to a weak solution of problem (3.1).

    Let

    Au,v:=T0eL(t)[12p(t)((c0Dαtu(t),ctDαTv(t))+(ctDαTu(t),c0Dαtv(t)))+p(t)(u(t),v(t))+(q(t)p(t))(u(t),v(t))]dt.

    Lemma 3.2. ([13])

    γ1u2Au,uγ2u2,for all uEα,20, (3.2)

    where γ1=|cos(πα)| and γ2=(max{Mm|cosπα|,1}+maxt[0,T](q(t)p(t))).

    Lemma 3.3. Assume that (F0), (f0) and (f1) (or (f0) and (f1)) hold. Then for each λ>0, ˜J is bounded from below on Eα,20 and satisfies (PS) condition.

    Proof. By (˜f1), (2.9) and (3.2), we have

    ˜J(u)=12Au,uλT0eL(t)˜F(t,u(t))dtγ12u2λmax{M1,M2}T0eL(t)(|u(t)|p1+|u(t)|p2)dtγ12u2λmax{M1,M2}Tmaxt[0,T]eL(t)(up1+up2)γ12u2λmax{M1,M2}Tmaxt[0,T]eL(t)[Bp1up1+Bp2up2].

    It follows from 0<p2<p1<2 that

    ˜J(u)+, as u.

    Hence, ˜J is coercive and then is bounded from below. Now we prove that ˜J satisfies the (PS) condition. Assume that {un} is a (PS) sequence of ˜J, that is,

    ˜J(un) is bounded, ˜J(un)0. (3.3)

    Then by the coercivity of ˜J and (3.3), there exists C0>0 such that unC0 and then by Lemma 2.3, there exists a subsequence (denoted again by {un}) such that

    unu, weakly in Eα,20, (3.4)
    unu, a.e.  in C([0,T],R). (3.5)

    Therefore, the boundness of {un} and (3.3) imply that

    |˜J(un),unu|˜J(un)(Eα,20)unu,˜J(un)(Eα,20)(un+u)0, (3.6)

    where (Eα,20) is the dual space of Eα,20, and (˜F0), (2.9) together with (3.5) imply that

    |λT0(˜F(t,un(t)),un(t)u(t))dt|λT0|˜F(t,un(t))||(un(t)u(t))|dtλunuT0[(1+ρ0)a0b(t)+M1p1|un(t)|p11+ρ0M1|un(t)|p1]dtλunu[(1+ρ0)a0T0b(t)dt+M1p1TBp11Cp110+M1Tρ0Bp1Cp10]0. (3.7)

    Note that

    ˜J(un),unu=Aun,unuλT0(˜F(t,un(t)),un(t)u(t))dt.

    Then (3.6) and (3.7) imply that limnAun,unu=0. Moreover, by (3.4), we have

    limnAu,unu=0.

    Therefore

    limnAunAu,unu=0.

    Since A is of type (S)+ (see [13]), by Definition 2.6, we obtain unu in Eα,20.

    Define a Nehari manifold by

    Nλ={uEα,20/{0}|˜Jλ(u),u=0}.

    Lemma 3.4. Assume that (F0) and (f0) (or (f0)) hold. For each λ>0, ˜Jλ has a nontrivial least energy (ground state) weak solution uλ, that is, uλNλ and ˜Jλ(uλ)=infNλ˜Jλ. Moreover, the least energy can be estimated as follows

    ˜Jλ(uλ)Gλ:=(p1/γ2)p12p1[λM1mint[0,T]eL(t)T0|w0(t)|p1dt]22p1(p12)2.

    where w0=ww, and w=(TπsinπtT,0,,0)Eα,20.

    Proof. By Lemma 3.3 and ˜JC1(Eα,20,R), for each λ>0, Lemma 2.5 implies that there exists some uλEα,20 such that

    ˜J(uλ)=infvEα,20˜J(v)and ˜J(uλ)=0. (3.8)

    By (3.2) and (˜f0), we have

    ˜Jλ(sw0)=12A(sw0),sw0λT0eL(t)˜F(t,sw0(t))dtγ22s2w02λT0eL(t)M1|sw0(t)|p1dtγ22s2λM1mint[0,T]eL(t)sp1T0|w0(t)|p1dt. (3.9)

    for all s[0,). Define g:[0,+)R by

    g(s)=γ22s2λM1mint[0,T]eL(t)sp1T0|w0(t)|p1dt.

    Then g(s) achieves its minimum at

    s0,λ=(p1λM1mint[0,T]eL(t)T0|w0(t)|p1dtγ2)12p1

    and

    g(s0,λ)=(p1/γ2)p12p1[λM1mint[0,T]eL(t)T0|w0(t)|p1dt]22p1(p12)2.

    Note that p1<2. So g(s0,λ)<0. Hence, (3.9) implies that

    ˜Jλ(uλ)=infvEα,20˜Jλ(v)˜Jλ(s0,λw0)g(s0,λ)<0=˜Jλ(0)

    and then uλ0 which together with (3.8) implies that uλNλ and ˜Jλ(uλ)=infNλ˜Jλ.

    Lemma 3.5. Assume that (F0), (f1) and (f2) hold. If 0<λ|cos(πα)|2C, then the following estimates hold

    uλ2p22λC|cos(πα)|,uλ2p22λCB2p2|cos(πα)|.

    Proof. It follows from Lemma 3.1, (2.9) and ˜J(uλ),uλ=0 that

    T0eL(t)[p(t)(c0Dαtuλ(t),ctDαTuλ(t))+p(t)(uλ(t),uλ(t))+(q(t)p(t))(uλ(t),uλ(t))]dt=λT0eL(t)(˜F(t,uλ(t)),uλ(t))dtλθT0eL(t)˜F(t,uλ(t))dtλθmax{M1,M2}maxt[0,T]eL(t)T0(|uλ(t)|p1+|uλ(t)|p2)dtλθmax{M1,M2}Tmaxt[0,T]eL(t)(uλp1+uλp2)λθmax{M1,M2}Tmaxt[0,T]eL(t)[Bp1uλp1+Bp2uλp2]λC(uλp1+uλp2). (3.10)

    We claim that uλ1 uniformly for all 0<λ|cos(πα)|2C. Otherwise, we have a sequence of {λn|cos(πα)|2C} such that uλn>1. Thus uλnp2<uλnp1 since p2<p1<2. By (2.10) and (3.10), we obtain

    T0eL(t)[p(t)(c0Dαtuλn(t),ctDαTuλn(t))+p(t)(uλn(t),uλn(t))+(q(t)p(t))(uλn(t),uλn(t))]dt|cos(πα)|uλn2+T0eL(t)(q(t)p(t))|uλn(t)|2dt. (3.11)

    By (3.10) and (3.11), we obtain

    |cos(πα)|uλn2+T0eL(t)(q(t)p(t))|uλn(t)|2dtλnC(uλnp1+uλnp2).

    Since q(t)p(t)>0,

    |cos(πα)|uλn2λnC(uλnp1+uλnp2)2λnCuλnp1.

    Then

    uλn2p12λnC|cos(πα)|1,

    which contradicts with the assumption uλn>1. Now, from (3.10) we can get

    |cos(πα)|uλ2λC(uλp1+uλp2)2λCuλp2.

    So

    uλ2p22λC|cos(πα)|.

    By (2.9), we can obtain

    uλBuλB(2λC|cos(πα)|)12p2.

    Observe that, in the proof of Lemma 3.5, (˜f2) is used only in (3.10). If we directly use (˜F0) to rescale (˜F(t,uλ(t)),uλ(t)) in (3.10). Then the assumption (f2) is not necessary but we have to pay the price that p(0,1). To be precise, we have the following lemma.

    Lemma 3.6. Assume that (F0) and (f0) hold. If 0<λ|cos(πα)|3C, then the following estimates hold

    uλ2p13λC|cos(πα)|,uλ2p13λCB2p1|cos(πα)|.

    Proof. It follows from (F0), Lemma 3.1, Remark 3.1, (2.9) and ˜J(uλ),uλ=0 that

    T0eL(t)[p(t)(c0Dαtuλ(t),ctDαTuλ(t))+p(t)(uλ(t),uλ(t))+(q(t)p(t))(uλ(t),uλ(t))]dt=λT0eL(t)(˜F(t,uλ(t)),uλ(t))dtλmaxt[0,T]eL(t)T0|˜F(t,uλ(t))||uλ(t)|dtλmaxt[0,T]eL(t)T0[(1+ρ0)a0b(t)|uλ(t)|+M1p1|uλ(t)|p1+ρ0M1|uλ(t)|p1+1]dtλmaxt[0,T]eL(t)[(1+ρ0)a0uλT0b(t)dt+M1p1uλp1+ρ0M1Tuλp1+1]λmaxt[0,T]eL(t)[(1+ρ0)a0BuλT0b(t)dt+M1p1TBp1uλp1+ρ0M1TBp1+1uλp1+1]λC(uλ+uλp1+uλp1+1). (3.12)

    We claim that uλ1 uniformly for all 0<λ|cos(πα)|3C. Otherwise, we have a sequence of {λn|cos(πα)|3C} such that uλn>1. Thus uλnp1<uλn<uλnp1+1 since p1<1. By (2.10) and (3.12), we obtain

    T0eL(t)[p(t)(c0Dαtuλn(t),ctDαTuλn(t))+p(t)(uλn(t),uλn(t))+(q(t)p(t))(uλn(t),uλn(t))]dt|cos(πα)|uλn2+T0eL(t)(q(t)p(t))|uλn(t)|2dt. (3.13)

    By (3.12) and (3.13), we obtain

    |cos(πα)|uλn2+T0eL(t)(q(t)p(t))|uλn|2dtλnC(uλ+uλp1+uλp1+1).

    Since q(t)p(t)>0,

    |cos(πα)|uλn2λnC(uλ+uλp1+uλp1+1)3λnCuλnp1+1.

    Then

    uλn1p13λnC|cos(πα)|1,

    which contradicts with the assumption uλn>1. Now, we can get from (3.12) that

    |cos(πα)|uλ2λC(uλ+uλp1+uλp1+1)3λCuλp1.

    So

    uλ2p13λC|cos(πα)|.

    By (2.9), we can obtain

    uλBuλB(3λC|cos(πα)|)12p1.

    Proof of Theorem 1.1. Since 0<λmin{|cos(πα)|2C,(1B)2p2(δ2)2p2|cos(πα)|2C}, Lemma 3.5 implies that

    uλδ2.

    Therefore, for all 0<λmin{|cos(πα)|2C,(1B)2p2(δ2)2p2|cos(πα)|2C}, we have ˜F(t,u(t))=F(t,u(t)) and then uλ is a nontrivial weak solution of the original problem (1.1). Moreover, Lemma 3.5 implies that limλ0uλ=0 as λ0 and

    uλ2p2min{1,(1B)2p2(δ2)2p2},uλ2p2B2p2{1,(1B)2p2(δ2)2p2}.

    Proof of Theorem 1.2. Note that 0<λmin{|cos(πα)|3C,(1B)2p1(δ2)2p1|cos(πα)|3C}. Similar to the proof of Theorem 1.1, by Lemma 3.6, it is easy to complete the proof.

    Proof of Theorem 1.3. By Lemma 3.1 and Lemma 3.3, we obtain that ˜J satisfies (PS) condition and is even and bounded from below, and ˜J(0)=0. Next, we prove that for any kN, there exists a subspace k-dimensional subspace XkEα,20 and ρk>0 such that

    supuXkSρk˜Jλ(u)<0.

    In fact, for any kN, assume that Xk is any subspace with dimension k in Eα,20. Then by (2.10) and Lemma 3.1, there exist constants C1,C2>0 such that

    ˜J(u)max{Mm|cos(πα)|,1}u2+12T0eL(t)(q(t)p(t))|u(t)|2dtλT0eL(t)˜F(t,u(t))dtmax{Mm|cos(πα)|,1}u2+C12u2λC2T0˜F(t,u(t))dtmax{Mm|cos(πα)|,1}u2+C1B22u2λC2M1T0|u(t)|p1dt[max{Mm|cos(πα)|,1}+C1B22]u2λC2M1up1Lp1.

    Since all norms on Xk are equivalent and p1<2, for each fixed λ>0, we can choose ρk>0 small enough such that

    supuXkSρk˜Jλ(u)<0.

    Thus, by Lemma 2.6 and Remark 2.3. ˜Jλ has a sequence of nonzero critical points {uλn}Eα,20 converging to 0 and ˜Jλ(uλn)0. Hence, for each fixed λ>0, (3.1) has a sequence of weak solutions {uλn}Eα,20 with uλn0, as n. Furthermore, there exists n0 large enough such that uλnδ2B for all nn0 and then (2.9) implies that uλnδ2 for all nn0. Thus, ˜F(t,u(t))=F(t,u(t)) and then {uλn}n0 is a sequence of weak solutions of the original problem (1.1) for each fixed λ>0.

    When the nonlinear term F(t,x) is local subquadratic only near the origin with respect to x, system (1.1) with λ in some given interval has a ground state weak solution uλ. If the nonlinear term F(t,x) is also locally even near the origin with respect to x, system (1.1) with λ>0 has infinitely many weak solutions {uλn}.

    This project is supported by Yunnan Ten Thousand Talents Plan Young & Elite Talents Project and Candidate Talents Training Fund of Yunnan Province (No: 2017HB016).

    The authors declare that they have no conflicts of interest.



    Conflict of interest



    The authors declare no conflict of interest.

    [1] Barrios CH (2022) Global challenges in breast cancer detection and treatment. Breast 62: S3-S6. https://doi.org/10.1016/j.breast.2022.02.003
    [2] Wilkinson L, Gathani T (2022) Understanding breast cancer as a global health concern. Br J Radiol 95: 20211033. https://doi.org/10.1259/bjr.20211033
    [3] Konieczna J, Chaplin A, Paz-Graniel I, et al. (2025) Adulthood dietary and lifestyle patterns and risk of breast cancer: Global Cancer Update Programme (CUP Global) systematic literature review. Am J Clin Nutr 121: 14-31. https://doi.org/10.1016/j.ajcnut.2024.10.003
    [4] Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6: 229-239. https://doi.org/10.1186/bcr932
    [5] Van Harten WH, Wind A, De Paoli P, et al. (2016) Actual costs of cancer drugs in 15 European countries. Lancet Oncol 17: 18-20. https://doi.org/10.1016/S1470-2045(15)00486-6
    [6] Malik JA, Jan R, Ahmed S, et al. (2022) Breast cancer drug repurposing a tool for a challenging disease, In: Saxena, S.K. Editor. Drug Repurposing—Molecular Aspects and Therapeutic Applications . https://doi.org/10.5772/intechopen.101378
    [7] Jourdan JP, Bureau R, Rochais C, et al. (2020) Drug repositioning: a brief overview. J Pharm Pharmacol 72: 1145-1151. https://doi.org/10.1111/jphp.13273
    [8] Preston IR, Klinger JR, Houtches J, et al. (2005) Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med 99: 1501-1510. https://doi.org/10.1016/j.rmed.2005.03.026
    [9] Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458: 719-724. https://doi.org/10.1038/nature07943
    [10] Ataollahi MR, Sharifi J, Paknahad MR, et al. (2015) Breast cancer and associated factors: a review. J Med Life 8: 6-11.
    [11] Akbar M, Akbar K, Naveed D (2014) Frequency and correlation of molecular subtypes of breast cancer with clinicopathological features. J Ayub Med Coll Abbottabad 26: 290-293.
    [12] Amjad A, Khan IK, Kausar Z, et al. (2018) Risk factors in breast cancer progression and current advances in therapeutic approaches to knockdown breast cancer. Clin Med Biochem 4. https://doi.org/10.4172/2471-2663.1000137
    [13] Zengel B, Yararbas U, Duran A, et al. (2015) Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast. Breast Cancer 22: 374-381. https://doi.org/10.1007/s12282-013-0489-8
    [14] Ward EM, DeSantis CE, Lin CC, et al. (2015) Cancer statistics: breast cancer in situ. CA Cancer J Clin 65: 481-495. https://doi.org/10.3322/caac.21321
    [15] Miklikova S, Trnkova L, Plava J, et al. (2021) The role of BRCA1/2-mutated tumor microenvironment in breast cancer. Cancers 13: 575. https://doi.org/10.3390/cancers13030575
    [16] Couto E, Hemminki K (2007) Estimates of heritable and environmental components of familial breast cancer using family history information. Br J Cancer 96: 1740-1742. https://doi.org/10.1038/sj.bjc.6603753
    [17] Pervaiz R (2017) Genetic mutations associated with breast cancer in Pakistan. Malays J Med Biol Res 4: 153-158. https://doi.org/10.18034/mjmbr.v4i2.439
    [18] Menhas R, Umer S (2015) Breast cancer among Pakistani women. Iran J Public Health 44: 586-587.
    [19] Zheng G, Yu H, Hemminki A, et al. (2017) Familial associations of female breast cancer with other cancers. Int J Cancer 141: 2253-2259. https://doi.org/10.1002/ijc.30927
    [20] Tinsley HN, Gary BD, Keeton AB, et al. (2011) Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res 4: 1275-1284. https://doi.org/10.1158/1940-6207.CAPR-11-0095
    [21] Bae SY, Kim S, Lee JH, et al. (2015) Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer 15: 138. https://doi.org/10.1186/s12885-015-1121-4
    [22] Ayoub NM, Al-Shami KM, Yaghan RJ (2019) Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer 11: 53-69. https://doi.org/10.2147/BCTT.S175360
    [23] Fabbro M, Savage K, Hobson K, et al. (2004) BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. J Biol Chem 279: 31251-31258. https://doi.org/10.1074/jbc.M405372200
    [24] Kast K, Rhiem K, Wappenschmidt B, et al. (2016) Prevalence of BRCA1/2 germline mutations in 21401 families with breast and ovarian cancer. J Med Genet 53: 465-471. https://doi.org/10.1136/jmedgenet-2015-103672
    [25] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317: 2402-2416. https://doi.org/10.1001/jama.2017.7112
    [26] Mavaddat N, Barrowdale D, Andrulis IL, et al. (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21: 134-147. https://doi.org/10.1158/1055-9965.EPI-11-0775
    [27] Shiovitz S, Korde LA (2015) Genetics of breast cancer: a topic in evolution. Ann Oncol 26: 1291-1299. https://doi.org/10.1093/annonc/mdv022
    [28] Tan MH, Mester JL, Ngeow J, et al. (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18: 400-407. https://doi.org/10.1158/1078-0432.CCR-11-2283
    [29] Lim W, Olschwang S, Keller JJ, et al. (2004) Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 126: 1788-1794. https://doi.org/10.1053/j.gastro.2004.03.014
    [30] Sharma S, Sambyal V, Guleria K, et al. (2014) Tp53 polymorphisms in sporadic north Indian breast cancer patients. Asian Pac J Cancer Prev 15: 6871-6879. https://doi.org/10.7314/apjcp.2014.15.16.6871
    [31] Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4. https://doi.org/10.1186/bcr426
    [32] Al-Joudi FS, Iskandar ZA, Rusli J (2008) The expression of p53 in invasive ductal carcinoma of the breast: a study in the north-east states of Malaysia. Med J Malaysia 63: 96-99.
    [33] Koo MM, von Wagner C, Abel GA, et al. (2017) Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: evidence from a national audit of cancer diagnosis. Cancer Epidemiol 48: 140-146. https://doi.org/10.1016/j.canep.2017.04.010
    [34] Gentile F, Elmenoufy AH, Ciniero G, et al. (2019) Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction. Chem Biol Drug Des 95: 460-471. https://doi.org/10.1111/cbdd.13660
    [35] Rosell R, Taron M, Ariza A, et al. (2004) Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31: 20-27. https://doi.org/10.1053/j.seminoncol.2003.12.011
    [36] Mantovani F, Collavin L, Del Sal G (2019) Mutant p53 as a guardian of the cancer cell. Cell Death Differ 26: 199-212. https://doi.org/10.1038/s41418-018-0246-9
    [37] Hientz K, Mohr A, Bhakta-Guha D, et al. (2017) The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget 8: 8921-8946. https://doi.org/10.18632/oncotarget.13475
    [38] Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, et al. (2018) Structural underpinnings of estrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer 18: 377-388. https://doi.org/10.1038/s41568-018-0001-z
    [39] Ham IH, Oh HJ, Jin H, et al. (2019) Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer 18: 68. https://doi.org/10.1186/s12943-019-0972-8
    [40] Wang Y, Qu Y, Niu XL, et al. (2011) Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 56: 365-375. https://doi.org/10.1016/j.cyto.2011.06.005
    [41] Song S, Wientjes MG, Gan Y, et al. (2000) Fibro-blast growth factors: an epigenetic mechanism of broad-spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A 97: 8658-8663. https://doi.org/10.1073/pnas.140210697
    [42] Singh S (2015) Cytoprotective and regulatory functions of glutathione-S-transferases in cancer cell proliferation and cell death. Cancer Chemother Pharmacol 75: 1-15. https://doi.org/10.1007/s00280-014-2566-x
    [43] Jena MK, Janjanam J (2018) Role of extracellular matrix in breast cancer development: a brief update. F1000Res 7: 274. https://doi.org/10.12688/f1000research.14133.2
    [44] Bukowski K, Kciuk M, Kontek R (2020) Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 21: 3233. https://doi.org/10.3390/ijms21093233
    [45] Wang X, Zhang H, Chen X (2019) Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2: 141-160. https://doi.org/10.20517/cdr.2019.10
    [46] Mesci S, Marakli S, Yazgan B, et al. (2019) The effect of ATP-binding cassette (ABC) transporters in human cancers. Int J Sci Lett 1: 14-19. https://doi.org/10.38058/IJSL.594000
    [47] Wu CP, Hsiao SH, Huang YH, et al. (2020) Sitravatinib sensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Cancers 12: 195. https://doi.org/10.3390/cancers12010195
    [48] Souza PS, Madigan JP, Gillet JP, et al. (2015) Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. Exp Cell Res 336: 318-328. https://doi.org/10.1016/j.yexcr.2015.06.005
    [49] Gorrini I, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12: 931-947. https://doi.org/10.1038/nrd4002
    [50] Zhang J, Wang X, Vikash V, et al. (2016) ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev 2016: 4350965. https://doi.org/10.1155/2016/4350965
    [51] Villeneuve N, Lau A, Zhang DD (2010) Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal 13: 1699-1712. https://doi.org/10.1089/ars.2010.3211
    [52] Rushmore TH, Pickett CB (1990) Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. J Biol Chem 265: 14648-14653.
    [53] Otsuki A, Yamamoto M (2020) Cis-element architecture of Nrf2-sMaf heterodimer binding sites and its relation to diseases. Arch Pharm Res 43: 275-285. https://doi.org/10.1007/s12272-019-01193-2
    [54] Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51-88. https://doi.org/10.1146/annurev.pharmtox.45.120403.095857
    [55] Sau A, Pellizzari Tregno F, Valentino F, et al. (2010) Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 500: 116-122. https://doi.org/10.1016/j.abb.2010.05.012
    [56] Meijerman I, Beijnen JH, Schellens JH (2008) Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 34: 505-520. https://doi.org/10.1016/j.ctrv.2008.03.002
    [57] Laborde E (2010) Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 17: 1373-1380. https://doi.org/10.1038/cdd.2010.80
    [58] Karin M, Gallagher E (2005) From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57: 283-295. https://doi.org/10.1080/15216540500097111
    [59] Wu Y, Fan Y, Xue B, et al. (2006) Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene 25: 5787-5800. https://doi.org/10.1038/sj.onc.1209576
    [60] Ho GY, Woodward N, Coward JI (2016) Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102: 37-46. https://doi.org/10.1016/j.critrevonc.2016.03.014
    [61] Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279. https://doi.org/10.1038/sj.onc.1206933
    [62] Pasello M, Michelacci F, Scionti I, et al. (2008) Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 68: 6661-6668. https://doi.org/10.1158/0008-5472.can-07-5840
    [63] Kankotia S, Stacpoole PW (2014) Dichloroacetate and cancer: new home for an orphan drug?. Biochim Biophys Acta 1846: 617-629. https://doi.org/10.1016/j.bbcan.2014.08.005
    [64] Jahn SC, Solayman MH, Lorenzo RJ, et al. (2016) GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate. Biochim Biophys Acta 1860: 1202-1210. https://doi.org/10.1016/j.bbagen.2016.01.024
    [65] Chen Y, Li Y, Huang L, et al. (2021) Antioxidative stress: inhibiting reactive oxygen species production as a cause of radioresistance and chemoresistance. Oxid Med Cell Longev 2021: 6620306. https://doi.org/10.1155/2021/6620306
    [66] Pirpour Tazehkand A, Salehi R, Velaei K, et al. (2020) The potential impact of trigonelline loaded micelles on Nrf2 suppression to overcome oxaliplatin resistance in colon cancer cells. Mol Biol Rep 47: 5817-5829. https://doi.org/10.1007/s11033-020-05650-w
    [67] Perez EA (2009) Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114: 195-201. https://doi.org/10.1007/s10549-008-0005-6
    [68] Szakacs G, Paterson JK, Ludwig JA, et al. (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234. https://doi.org/10.1038/nrd1984
    [69] Liang XJ, Chen C, Zhao Y, et al. (2010) Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol 596: 467-488. https://doi.org/10.1007/978-1-60761-416-6_21
    [70] Saxena M, Stephens MA, Pathak H, et al. (2011) Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2: e179. https://doi.org/10.1038/cddis.2011.61
    [71] Ambudkar SV, Dey S, Hrycyna CA, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398. https://doi.org/10.1146/annurev.pharmtox.39.1.361
    [72] Shen DW, Goldenberg S, Pastan I, et al. (2000) Decreased accumulation of [14C] carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 183: 108-116. https://doi.org/10.1002/(SICI)1097-4652(200004)183:1<108::AID-JCP13>3.0.CO;2-4
    [73] Lowe SW, Ruley HE, Jacks T, et al. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967. https://doi.org/10.1016/0092-8674(93)90719-7
    [74] Liu Y, Han TY, Giuliano AE, et al. (2001) Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15: 719-730. https://doi.org/10.1096/fj.00-0223com
    [75] Di X, Gennings C, Bear HD, et al. (2010) Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 124: 349-360. https://doi.org/10.1007/s10549-010-0765-7
    [76] Ahmed WS, Geethakumari AM, Biswas KH (2021) Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother 134: 111128. https://doi.org/10.1016/j.biopha.2020.111128
    [77] Al-Shboul O, Mahavadi S, Sriwai W, et al. (2013) Differential expression of multidrug resistance protein 5 and phosphodiesterase 5 and regulation of cGMP levels in phasic and tonic smooth muscle. Am J Physiol Gastrointest Liver Physiol 305: G314-G324. https://doi.org/10.1152/ajpgi.00457.2012
    [78] Paronetto MP, Crescioli C (2024) Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health. Front Endocrinol 15: 1461642. https://doi.org/10.3389/fendo.2024.1461642
    [79] Peng T, Gong J, Jin Y, et al. (2018) Inhibitors of phosphodiesterase as cancer therapeutics. Eur J Med Chem 150: 742-756. https://doi.org/10.1016/j.ejmech.2018.03.046
    [80] Catalano S, Campana A, Giordano C, et al. (2016) Expression and function of phosphodiesterase type 5 in human breast cancer cell lines and tissues: implications for targeted therapy. Clin Cancer Res 22: 2271-2282. https://doi.org/10.1158/1078-0432.ccr-15-1900
    [81] Gong L, Lei Y, Tan X, et al. (2019) Propranolol selectively inhibits cervical cancer cell growth by suppressing the cGMP/PKG pathway. Biomed Pharmacother 111: 1243-1248. https://doi.org/10.1016/j.biopha.2019.01.027
    [82] Lee K, Piazza GA (2017) The interaction between the Wnt/β-catenin signaling cascade and PKG activation in cancer. J Biomed Res 31: 189-196. https://doi.org/10.7555/JBR.31.20160133
    [83] Jedlitschky G, Burchell B, Keppler D (2000) The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275: 30069-30074. https://doi.org/10.1074/jbc.M005463200
    [84] Zhang Z, Huang W, Huang D, et al. (2025) Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription. Commun Biol 8: 85. https://doi.org/10.1038/s42003-025-07519-9
    [85] Ribeiro E, Costa B, Vasques-Nóvoa F, et al. (2023) In vitro drug repurposing: focus on vasodilators. Cells 12: 671. https://doi.org/10.3390/cells12040671
    [86] Jang GB, Kim JY, Cho SD, et al. (2015) Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci Rep 5: 12465. https://doi.org/10.1038/srep12465
    [87] Raut D, Vora A, Bhatt LK (2022) The Wnt/β-catenin pathway in breast cancer therapy: a pre- clinical perspective of its targeting for clinical translation. Expert Rev Anticancer Ther 22: 97-114. https://doi.org/10.1080/14737140.2022.2016398
    [88] Wang JQ, Wu ZX, Yang Y, et al. (2021) ATP-binding cassette (ABC) transporters in cancer: a review of recent updates. J Evid Based Med 14: 232-256. https://doi.org/10.1111/jebm.12434
    [89] Duan C, Yu M, Xu J, et al. (2023) Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother 162: 114643. https://doi.org/10.1016/j.biopha.2023.114643
    [90] Koehn LM (2022) ABC transporters: an overview. https://doi.org/10.1007/978-3-030-51519-5_76-1
    [91] Engle K, Kumar G (2022) Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update. Eur J Med Chem 239: 114542. https://doi.org/10.1016/j.ejmech.2022.114542
    [92] Sajid A, Rahman H, Ambudkar SV (2023) Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer 23: 762-779. https://doi.org/10.1038/s41568-023-00612-3
    [93] Skinner KT, Palkar AM, Hong AL (2023) Genetics of ABCB1 in cancer. Cancers 15: 4236. https://doi.org/10.3390/cancers15174236
    [94] Zhou HM, Zhang JG, Zhang X, et al. (2021) Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther 6: 62. https://doi.org/10.1038/s41392-020-00430-1
    [95] Ni Y, Zhou X, Yang J, et al. (2021) The role of tumor-stroma interactions in drug resistance within tumor microenvironment. Front Cell Dev Biol 9: 637675. https://doi.org/10.3389/fcell.2021.637675
    [96] Karunarathna I, De Alvis K, Gunasena P, et al. (2024) The impact of sildenafil on quality of life: evidence from clinical studies. In: Comprehensive Insights on Intensive Care, Anaesthesia, and Pain Management: An Article Compilation. Charlottesville: UVA-Clinical Pharmacology, 179-182.
    [97] Chhonker SK, Rawat D, Koiri RK (2022) Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance. J Biochem Mol Toxicol 36: e23100. https://doi.org/10.1002/jbt.23100
    [98] Bhattacharjya D, Sivalingam N (2024) Mechanism of 5-fluorouracil induced resistance and role of piperine and curcumin as chemo-sensitizers in colon cancer. Naunyn Schmiedebergs Arch Pharmacol 397: 8445-8475. https://doi.org/10.1007/s00210-024-03189-2
    [99] Gu Y, Yang R, Zhang Y, et al. (2025) Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Mol Biomed 6: 2. https://doi.org/10.1186/s43556-024-00239-2
    [100] Ebrahimnezhad M, Asl SH, Rezaie M, et al. (2024) lncRNAs: new players of cancer drug resistance via targeting ABC transporters. IUBMB Life 76: 883-921. https://doi.org/10.1002/iub.2888
    [101] Goebel J, Chmielewski J, Hrycyna CA (2021) The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors. Cancer Drug Resist 4: 784-804. https://doi.org/10.20517/cdr.2021.19
    [102] Angelis I, Moussis V, Tsoukatos DC, et al. (2021) Multidrug resistance protein 4 (MRP4/ABCC4): a suspected efflux transporter for human's platelet activation. Protein Pept Lett 28: 983-995. https://doi.org/10.2174/0929866528666210505120659
    [103] Yin Q, Zheng X, Song Y, et al. (2023) Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases. Front Pharmacol 14: 1272073. https://doi.org/10.3389/fphar.2023.1272073
    [104] Kuzmiszyn AK (2023) Temperature-dependent effects of phosphodiesterase inhibitors for cardiovascular support in hypothermic patients-Effects on cellular elimination of cAMP and cGMP. Available from: https://hdl.handle.net/10037/31584
    [105] Liu R, Chen Y, Liu G, et al. (2020) PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 11: 797. https://doi.org/10.1038/s41419-020-02998-6
    [106] He Y, Sun MM, Zhang GG, et al. (2021) Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6: 425. https://doi.org/10.1038/s41392-021-00828-5
    [107] Dong C, Wu J, Chen Y (2021) Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol 12: 628690. https://doi.org/10.3389/FPHAR.2021.628690
    [108] Booth L, Albers T, Roberts JL, et al. (2016) Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. Oncotarget 7: 40398-40417. https://doi.org/10.18632/oncotarget.9752
    [109] Greish K, Sawa T, Fang J, et al. (2004) SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J Control Release 97: 219-230. https://doi.org/10.1016/j.jconrel.2004.03.027
    [110] Black KL, Yin D, Ong JM, et al. (2008) PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 1230: 290-302. https://doi.org/10.1016/j.brainres.2008.06.122
    [111] Mehrotra N, Gupta M, Kovar A, et al. (2007) The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 19: 253-264. https://doi.org/10.1038/sj.ijir.3901522
    [112] Zhang P, Zhang Y, Ding X, et al. (2020) Enhanced nanoparticle accumulation by tumor-acidity-activatable release of sildenafil to induce vasodilation. Biomater Sci 8: 3052-3062. https://doi.org/10.1039/D0BM00466A
    [113] Abd El-Aziz YS, Spillane AJ, Jansson PJ, et al. (2021) Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers. Biosci Rep 41: BSR20204092. https://doi.org/10.1042/BSR20204092
    [114] Rad SK, Yeo KKL, Li R, et al. (2025) Enhancement of doxorubicin efficacy by Bacopaside II in triple-negative breast cancer cells. Biomolecules 15: 55. https://doi.org/10.3390/biom15010055
    [115] Chen JJ, Sun YL, Tiwari AK, et al. (2012) PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Sci 103: 1531-1537. https://doi.org/10.1111/j.1349-7006.2012.02328.x
    [116] El-Naa MM, Othman M, Younes S (2016) Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Dev Ther 10: 3661-3672. https://doi.org/10.2147/DDDT.S107490
    [117] Booth L, Roberts JL, Cruickshanks N, et al. (2015) PDE5 inhibitors enhance celecoxib killing in multiple tumor types. J Cell Physiol 230: 1115-1127. https://doi.org/10.1002/jcp.24843
    [118] Hassanvand F, Mohammadi T, Ayoubzadeh N, et al. (2020) Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells. J Cancer Res Ther 16: 1412-1418. https://doi.org/10.4103/jcrt.JCRT_675_19
    [119] Greish K, Fateel M, Abdelghany S, et al. (2018) Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer. J Drug Target 26: 610-615. https://doi.org/10.1080/1061186X.2017.1405427
    [120] Webb T, Carter J, Roberts JL, et al. (2015) Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. Cancer Biol Ther 16: 1660-1670. https://doi.org/10.1080/15384047.2015.1099769
    [121] Chen L, Liu Y, Becher A, et al. (2020) Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2. Carcinogenesis 41: 1421-1431. https://doi.org/10.1093/carcin/bgaa001
  • This article has been cited by:

    1. Ji Hyun Yun, Eunsol Lee, Jeong Hwa Choi, Hyun Kyun Ki, Jiho Park, Seroprevalence of Varicella-Zoster Virus and Measles among Healthcare Workers in a Tertiary Medical Center in Korea, 2022, 10, 2076-393X, 1956, 10.3390/vaccines10111956
    2. Ayako Suzuki, Hiroshi Nishiura, Seasonal transmission dynamics of varicella in Japan: The role of temperature and school holidays, 2022, 20, 1551-0018, 4069, 10.3934/mbe.2023190
    3. Lingling Wang, Xu Yang, Xuwen Wang, Ping Shi, Xuhui Zhang, Assessing vaccine effectiveness for varicella in Wuxi, China: a time-series analysis, 2023, 55, 0785-3890, 10.1080/07853890.2023.2246369
    4. Cheng-Cheng Zhu, Jiang Zhu, Jie Shao, Epidemiological Investigation: Important Measures for the Prevention and Control of COVID-19 Epidemic in China, 2023, 11, 2227-7390, 3027, 10.3390/math11133027
    5. S. Hariharan, L. Shangerganesh, A. Debbouche, V. Antonov, Stability analysis of spatiotemporal reaction–diffusion mathematical model incorporating the varicella virus transmission, 2023, 138, 2190-5444, 10.1140/epjp/s13360-023-04777-6
    6. Ulrikka Nygaard, Mette Holm, Helena Rabie, Maren Rytter, The pattern of childhood infections during and after the COVID-19 pandemic, 2024, 8, 23524642, 910, 10.1016/S2352-4642(24)00236-0
    7. Ana Clara Poncheke Ratto, Lara De Camargo Stein, Letícia Dardes Barbosa , Marina Fernandes Xavier , Milena Roberta Freire da Silva, The Impacts of Social Isolation and Vaccination on cases of Varicella in Brazil: An Ecological Study, 2025, 9, 2675-1542, 10.53843/bms.v9i13.760
    8. Chunmei Duan, Yan Zhang, Qian Zhang, Shuzhi Zhang, Peisong Zhong, Gang Gong, Yefan Zhu, Jie Fei, Jingjing Zhao, Yanling Sun, Yaqing Jin, Yunjie Ren, Yihan Lu, Ye Yao, Hongjie Yu, Impact of natural and socio-economic factors on varicella incidence in children in Shanghai, 2013-2022, 2025, 13, 2296-2565, 10.3389/fpubh.2025.1565717
  • Reader Comments
  • © 2025 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(379) PDF downloads(45) Cited by(0)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog